Acute Bacterial Pneumonia in Rats Increases Alveolar Epithelial Fluid Clearance by a Tumor Necrosis Factor–Alpha–dependent Mechanism

S. Rezaiguia, C. Garat, C. Delclaux, M. Meignan, J. Fleury, P. Legrand, M.A. Matthay, and C. Jayr

Department of Anesthesia, Institut National de la Santé et de la Recherche Medicale U 296, Department of Nuclear Medicine, Department of Pathology, and Department of Microbiology, Hôpital Henri Mondor, 94010 Créteil, France; Cardiovascular Research Institute and Department of Anesthesia and Medicine, University of California, San Francisco, California 94143; and Department of Anesthesia, Institut Gustave Roussy, 94805 Villejuif, France

Abstract

To study the rate and regulation of alveolar fluid clearance in acute pneumonia, we created a model of Pseudomonas aeruginosa pneumonia in rats. To measure alveolar liquid and protein clearance, we instilled into the airspaces a 5% bovine albumin solution with 1.5 μCi of 125I-human albumin, 24 h after intratracheal instillation of bacteria. The concentration of unlabeled and labeled protein in the distal airspaces over 1 h was used as an index of net alveolar fluid clearance. Since there was histologic evidence of alveolar epithelial injury, several methods were used to measure alveolar fluid clearance, including the use of experiments in rats with blood flow and the use of experiments in rats without blood flow, so that movement across the epithelial barrier would be minimized in the latter group. The results with each method were identical. We found that P. aeruginosa pneumonia increased alveolar liquid clearance over 1 h by 48% in studies with blood flow, and by 43% in rats without blood flow, compared with respective controls (P < 0.05). In both studies, this increase was inhibited with amiloride. However, propranolol had no inhibitory effect, thus ruling out a catecholamine-dependent mechanism to explain the increase in alveolar fluid clearance. An anti–tumor necrosis factor–α neutralizing antibody, instilled into the lung 5 min before bacteria, prevented the increase in alveolar liquid clearance in rats with pneumonia (P < 0.05). Also, TNFα (5 μg) instilled in normal rats increased alveolar liquid clearance by 43% over 1 h compared with control rats (P < 0.05). In normal rats instilled with TNFα, propranolol had no inhibitory effect. In conclusion, gram-negative pneumonia markedly upregulates net alveolar epithelial fluid clearance, in part by a TNFα-dependent mechanism. This finding provides a novel mechanism for the upregulation of alveolar epithelial sodium and fluid transport from the distal airspaces of the lung. (J. Clin. Invest. 1997. 99:325–335.)

Key words: alveolar epithelium • tumor necrosis factor–α • anti–tumor necrosis factor–α antibody • Pseudomonas aeruginosa • pneumonia

Introduction

Several animal and human studies have established active sodium transport as the primary mechanism driving alveolar liquid clearance in the normal lung (1–3). The alveolar epithelial barrier may play a critical role in regulating alveolar liquid clearance under certain pathological conditions. Septic shock in rats is associated with increased alveolar epithelial fluid clearance (4). Rats exposed to sublethal hyperoxia have increased clearance mediated by stimulated alveolar epithelial sodium uptake (5, 6). Also, instillation of endotoxin into the rat lungs results in the upregulation of sodium transport and alveolar liquid clearance at 24 and 40 h (7).

One of the most frequent causes of nosocomial pneumonia, Pseudomonas aeruginosa, is associated with a high mortality (8, 9) and is a common cause of clinical acute lung injury (10). An understanding of the factors that may regulate alveolar epithelial transport in the presence of pneumonia is of major importance. We therefore studied the function of the alveolar epithelial barrier in a model of established P. aeruginosa pneumonia in rats.

The first objective of the study was to investigate the hypothesis that the alveolar administration of P. aeruginosa organisms would stimulate alveolar epithelial liquid clearance in anesthetized rats. Alveolar fluid clearance was measured by the progressive change in protein concentration of fluid instilled into the airspaces over 1 h, as we have previously described (3, 11, 12). Adjustments for the loss of alveolar protein were made by measuring residual 125I-albumin in the lung, as we have done before (12), and by measuring the dilution of the instilled 125I-albumin in the airspaces, a new method developed for this study. Since there was evidence for an increase in alveolar epithelial liquid clearance, the second objective was to study the mechanism by administering amiloride, a sodium transport inhibitor, and propranolol, a beta-adrenergic antagonist, into the distal airspaces of the rats with pneumonia. Although TNFα has been reported to play a role in increased lung epithelial permeability in acute lung injury (13), TNFα has also been reported to increase sodium-dependent amino acid transport in rat hepatocytes (14). Therefore, our third objective was to test the hypothesis that TNFα mediates the bacterially induced increase in alveolar fluid clearance.

Methods

Pathogen-free male Sprague Dawley rats (mean weight, 370 g) were used. The rats were housed in air-filtered, temperature-controlled units with food and water.

Experimental preparation

Bacterial pneumonia, neutralizing anti–TNFα antibody, and TNFα treatment. Rats were anesthetized by halothane administration via a
face mask. A median incision was performed in the anterior neck to expose the trachea, and two successive intratracheal instillations using 25-gauge needles were performed. Rats were allocated randomly to receive 0.1 ml either saline or anti-TNFα antibody (Ab) solution (see below for details), and ~5 min later, 0.5 ml/kg either saline or bacterial solution (P. aeruginosa). We therefore studied rats with pneumonia (P. aeruginosa), rats with pneumonia pretreated with anti–TNFα antibody (P. aeruginosa + Ab), normal rats (saline), and TNFα antibody–treated rats. Bacterial administration consisted of instillation of a P. aeruginosa saline solution (4–8 × 10^6 CFU/ml, see below for details). A total of 181 surviving pneumonia and normal rats were studied.

**P. aeruginosa inoculum preparation and bacteriology.** Preliminary dose-response studies established the inoculum of live P. aeruginosa required to induce pneumonia 24 h after intratracheal instillation. The size of the bacterial inoculum was selected so that the quantitative pulmonary tissue culture would yield ≥10^6 CFU per gram of tissue in all rats with pneumonia at 24 h. A nonmocked P. aeruginosa strain (serotype 11) was used for all studies. These bacteria were maintained in peptone broth containing 25% glycerol at ~70°C. Before each experiment, the strain was propagated in tryptophane soy agar plates for 24 h at 37°C. One colony was then transferred to tryptone soy broth for another 24 h at 37°C. On the day of the experiment, the bacteria were centrifuged at 3,000 g for 15 min and the pellet of bacteria was washed twice with phosphate buffered saline. P. aeruginosa solution was finally resuspended in saline at a concentration of 4–8 × 10^6 CFU/ml, and 0.5 ml/kg of this solution was intratracheally instilled in rats. A sample of bacterial solution was taken for quantitative culture. Samples of blood, pleural lavage liquid, and lung homogenate were obtained aseptically for culture in pneumonia rats 24 h after the bacterial instillation. The concentration of bacteria was then quantified by placing successive 10-fold dilutions of the bacterial suspension in tryptone soy agar plates and scoring visible colonies after a 24-h incubation at 37°C. Regular routine biochemical screening and antibiotic sensitivity testing were done to ensure that the P. aeruginosa strain had not changed between experiments.

**Neutralizing anti–TNFα antibody.** The polyclonal anti–mouse TNFα antibody (Genzyme Corp., Dako, France) used in these studies has been shown to neutralize rat TNFα in vivo (15). To establish the neutralizing dose for these experiments, the antibody was used in several dilutions including 1:10,000, 1:1,000, 1:300, and 1:100; 1:100 was found to neutralize 70% of immonoreactive TNFα in the lungs (see Fig. 5).

**TNFα.** TNFα (recombinant mouse TNFα, Genzyme Corp.) was given intratracheally in normal rats. We used a dose of 5 µg, previously shown to induce a protective effect against oxygen toxicity in vivo in rats (16).

**Specific experimental groups and procedures for these studies**

Alveolar liquid and protein clearance was measured 24 h after instillation of the bacteria because there was histologic evidence of pneumonia at this time. The effects of amiloride or propranolol, potential inhibitors of alveolar liquid clearance, were studied in rats with pneumonia. To investigate the role of TNFαs, experiments were done in pneumonia rats treated with neutralizing anti–TNFα antibody, in normal rats treated acutely either with TNFα or TNFα plus propranolol. Normal rats treated with neutralizing anti–TNFα antibody were studied.

The specific protocol for the individual groups for measurement of alveolar liquid clearance (ALC) were: P. aeruginosa group (n = 14), P. aeruginosa + Ab group (n = 6), control group (n = 10), and Ab group (n = 5). Additionally, ALC was performed immediately after supplemental instillation of either (a) propranolol (P. aeruginosa + prop, n = 10) or amiloride (P. aeruginosa + amil, n = 9) in rats with pneumonia, or (b) TNFα (TNFα, n = 4) or TNFα plus propranolol (TNFα + prop, n = 4) in normal rats.

24 h after the intratracheal instillations of saline, bacteria, or anti–TNFα antibody, the following previously described procedure was used (11). The rats were anesthetized (intraperitoneal pentobarbital sodium, 50 mg/kg, and pancuronium bromide, 0.5 mg/kg) and ventilated supine through an endotracheal tube (tidal volume = 7–8 ml/kg) (rodent ventilator No. 683; Harvard Apparatus, Inc., South Natick, MA) with a FiO2 of 1.0, a respiratory rate of 60/min and a positive end expiratory pressure of 3 cm H2O. Arterial pressure was continuously monitored through a carotid arterial line. Body temperature was kept constant at 38°C with a thermostatically controlled pad. After a 30-min postsurgery baseline of stable heart rate and blood pressure, 1.5 µCi 125I-labeled human serum albumin was intravascularly injected. 15 min later, a 5% bovine albumin Ringer’s lactate solution (6 ml/kg) with 1.5 µCi 125I-labeled human serum albumin was delivered into both lungs over 1 min via the trachea. In some experiments in pneumonia rats, either amiloride 2 × 10^−3 M (Sigma Chemical Co, France) (P. aeruginosa + amil group) or propranolol 10^−3 M (Sigma Chemical Co.) (P. aeruginosa + prop group) were added to the instilled albumin test solution. In TNFα-treated groups, normal rats were intratracheally instilled with the 5% albumin solution mixed with either 5 µg TNFα (TNFα group), or TNFα plus propranolol 10^−3 M (TNFα + prop group). After a 1-h ventilation, a sample of alveolar fluid (0.2–0.3 ml) was aspirated using a 5-ml syringe and silastic tubing that was passed into a wedged position in both lungs. The lungs were then removed through a mid-line sternotomy. Blood samples were obtained at the beginning and after 1 h. The total protein concentration and the radioactivity of the instillate, blood, and alveolar fluid samples were measured. Radioactivity counts were also measured in the lungs.

**Protocol to validate measurement of alveolar liquid clearance**

The details for the methods for calculation of ALC are provided in the measurements section of the Methods. To validate this method in the injured lung, several experimental approaches were used.

First, the instilled 5% albumin solution with 125I-albumin was sampled over 1 min after instillation into the airspaces of the rats with pneumonia, to measure the change in the concentration of the labeled and the unlabeled protein, and then taking into account the dilution by nonlabeled protein-rich alveolar edema fluid. To be certain that the 125I and 123I labels remained attached to the albumin, and that the albumin was not denatured during the experiment, electrophoresis over a 10–15% gradient polyacrylamide gel (Phast System; Pharmacia LKB Biotechnology Inc., Piscataway, NJ) was carried out on samples of blood and fluid aspirated from the airspaces 1 min and 60 min after instillation in rats with pneumonia. In addition, the osmolality of the initial (312±5 mosM) and final (312±23 mosM) alveolar fluid samples were measured in four rats.

Second, we eliminated bidirectional protein movement by exsanguinating rats and measuring alveolar fluid clearance over 1 h, as we have done in sheep (17) and in excised human lungs (2, 18). In these previous studies (2, 17, 18), it has been shown that alveolar fluid clearance does not depend on blood flow. Thus, studies without blood flow were conducted in exsanguinated (Exs.) pneumonia rats (Exs. P. aeruginosa group, n = 4), and the effects of propranolol or amiloride were measured (Exs. P. aeruginosa + prop group, n = 4, and Exs. P. aeruginosa + amil group, n = 4). For controls, normal exsanguinated rats were used. In these studies without blood flow, exsanguination was done before the intratracheal instillation of the albumin solution.

**Extravascular lung water**

The effect of live alveolar P. aeruginosa and anti–TNFα antibody on extravascular lung water was measured in each group. At the end of the experimental period, the animals were exsanguinated and the lungs were removed and processed for gravimetric determination of extravascular water and dry weight as in our earlier studies (7, 20).
Bronchoalveolar lavage and differential cell count
The recruitment of inflammatory cells associated with P. aeruginosa alone, anti–TNFα antibody alone, or both anti–TNFα antibody and P. aeruginosa instillations into the airspaces was examined in 28 rats. Rats were anesthetized, exsanguinated, and the trachea was exposed. Bronchoalveolar lavage (BAL) was carried out by flushing the lungs nine times with 2.5 ml of 37°C sterile pyrogen-free physiological saline via the tracheal cannula. The first fraction was removed. The eight other fractions of 2.5 ml were recovered and pooled. The total number of cells was counted using a standard hemocytometer. Cytospin preparations were made using a Shandon 3 cytocentrifuge (Shandon, France). The cells were air-dried and stained by May-Grünwald Giemsa. Differential cell counts on 200 cells were made using standard morphological criteria.

Histologic examination
Light microscopy and transmission electron microscopy were carried out in infected and normal rats, without the observer’s knowledge of the specific experimental protocol. Rats were prepared as in BAL procedure.

Light microscopy. Lungs were processed by inflating with 10 ml Bouin’s fixative (in situ fixation), followed by immersion in fixative solution. Two parasagittal sections were made of each lung and processed in the routine manner for paraffin embedding.

Transmission electron microscopy. Lungs were fixed in situ by inflating 10 ml of 2.5% glutaraldehyde in cacodylate buffer followed by immersion in fixative. Blocks of tissue were then postfixed in osmium tetroxide and embedded in epon as usual. Ultrastructure sections were observed under an EM 301 microscope (Philips, Eindhoven, Netherlands).

Protocol for TNFα measurements
Pulmonary rat TNFα levels were measured (see Measurements for details) in normal rats instilled with saline and in rats instilled with P. aeruginosa, before and at fixed times after the instillation (30 min, 1, 2, 4, 6, 12, and 24 h). TNFα levels were also measured in rats with pneumonia pretreated with different concentrations of anti–TNFα antibody to determine the necessary concentration of antibody to reduce TNFα levels in the lungs. These studies were done 4 h after the tracheal instillation, corresponding to the peak TNFα levels (see Fig. 4). Rats were anesthetized and exsanguinated; the lungs were then removed and stored at −80°C until measurement of TNFα.

Measurements
**Hemodynamics, airway pressure, and arterial blood gases.** Systemic arterial and airway pressures were monitored continuously with pressure transducers (Baxter Healthcare Corp., Deerfield, IL) recorded with a computer system (Windo Graf Gould, France). Arterial blood gases were measured before and 30 min after the instillation of the 5% albumin solution.

**Protein concentration and hemoglobin measurement.** Protein concentration was measured by the biuret method. Hemoglobin was measured spectrophotometrically (VP 10.12; Jouan, France) on the blood samples and on the supernatant obtained after centrifugation of lung homogenate (15,000 g for 1 h).

**TNFα levels measurement.** Pulmonary rat TNFα levels were measured in duplicate in the lung homogenate using an enzyme-linked immunosorbent assay system that uses a monoclonal anti-mouse TNFα antibody (Factor-Test-X™ Mouse TNFα ELISA Kit; Genzyme Corp.). The results were analyzed spectrophotometrically using an MR600 microplate reader (Dynatech Laboratories, Inc., Chantilly, VA) and TNFα levels were expressed as picograms per milliliter. Accurate sample concentrations of TNFα were determined by comparing their respective absorbances with those obtained for the standards plotted on a standard curve. This immunoreactive method has been shown to be accurate for measuring TNFα in rats (19).

**Extravascular lung water.** Extravascular lung water was determined as it has been described previously (11, 20) by calculating the water to dry weight ratio.

**Alveolar liquid clearance.** ALC (percent loss over 1 h from alveolar space of the volume of liquid instilled) was measured by the increase in the final unlabeled alveolar protein concentration, compared with the initial instilled alveolar protein concentration as in earlier studies (3, 7, 11, 20). ALC was calculated as ALC = (Vf × Fw)/(Vi × Fw) × 100.

Fr is the fraction of alveolar tracer ([125I-albumin]) protein that remains in the lung at the end of the experiment.

The concentration of the alveolar [125I]-albumin can also be used to estimate alveolar liquid clearance (11, 20). The volume of the final alveolar fluid was then estimated as Vf = (Vi × TP × Fr)/TP,

**TP** is the total protein concentration of the initial (i) and final (f) alveolar fluid. Fr is the fraction of alveolar tracer ([125I-albumin]) protein that remains in the lung at the end of the experiment.

Alveolar barrier protein flux. The bidirectional flux of albumin across the alveolar barrier was calculated by measuring (a) the residual [125I-albumin] (the alveolar protein tracer) in the lung as well as the accumulation of [125I]-albumin in the plasma, and (b) the clearance of [125I]-albumin (the vascular protein tracer) into the extravascular spaces of the lung (3, 12, 21–23). The measurement of the two tracers was made over a 1-h period 24 h after the bacterial instillation.

The clearance from the lung of [125I]-albumin was determined by multiplying the total radioactivity of the [125I]-albumin in the instillate by the volume that was instilled. The [125I]-albumin remaining in the lungs was directly measured by counting the radioactivity of the lungs. This value was then divided by the instilled radioactivity and expressed as a percentage of the instilled tracer. Total [125I]-albumin in blood was measured by the total counts of [125I]-albumin in the plasma at the end of the experiment multiplied by the plasma volume (see below). The total [125I]-albumin in the plasma was then divided by the total instilled [125I]-albumin for determination of the percentage of the [125I]-albumin instilled in the plasma.

The plasma volume was calculated as volume plasma = body weight in grams × (1 – hematocrit/100) × 0.07. To be certain of the accuracy of the calculation of plasma volume, the plasma volume was also measured by the dilution of either a label for plasma ([131I]-albumin) or a label for erythrocytes ([125I]-Ct) and plasma ([125I]-albumin). No difference was found between the methods; therefore, we could use the two measurement methods interchangeably.

The clearance of [131I]-albumin (the vascular protein tracer) in the extravascular and in the alveolar spaces of the lung was used as an index of endothelial permeability (22, 24). To calculate the amount of [131I]-albumin present in the extravascular spaces of the lung, we deducted the counts of the blood in the lung from the [125I]-albumin...
Table I. Effect of P. aeruginosa and Anti–TNFα Antibody on Bacterial Counts in the Lung Homogenate, Pleural Lavage Liquid, and the Blood

<table>
<thead>
<tr>
<th>Experimental condition</th>
<th>No.</th>
<th>Quantitative culture</th>
<th>Qualitative culture</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>cfu/g</td>
<td>% of positive</td>
</tr>
<tr>
<td>Surviving rats at 24 h</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Control + Ab</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>P. aeruginosa</td>
<td>4</td>
<td>2.8±4.8×10^2</td>
<td>50</td>
</tr>
<tr>
<td>P. aeruginosa + Ab</td>
<td>4</td>
<td>3.0±4.6×10^2</td>
<td>50</td>
</tr>
<tr>
<td>Spontaneous death within 24 h</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P. aeruginosa</td>
<td>2</td>
<td>5.0±7.0×10^6</td>
<td>100</td>
</tr>
<tr>
<td>P. aeruginosa + Ab</td>
<td>2</td>
<td>5.5±6.0×10^6</td>
<td>100</td>
</tr>
</tbody>
</table>

Data as mean±SD. *P < 0.05 compared with surviving rats with pneumonia. 4–8×10^6 cfu/kg weight was instilled.

Table II. Effect of P. aeruginosa and Anti–TNFα Antibody Instillation on Influx of Cells into the Airspaces over 4 and 24 h

<table>
<thead>
<tr>
<th>Experimental condition</th>
<th>No.</th>
<th>Total cells</th>
<th>Neutrophils</th>
<th>Macrophages</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>4 h</td>
<td>24 h</td>
<td>4 h</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10^6/ml of BAL</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>% of total number cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>3</td>
<td>2.3±0.7</td>
<td>2.7±1.0</td>
<td>0.5±0.1</td>
</tr>
<tr>
<td>Control + Ab</td>
<td>3</td>
<td>2.8±0.9</td>
<td>3.2±0.5</td>
<td>0.8±0.5</td>
</tr>
<tr>
<td>P. aeruginosa</td>
<td>5</td>
<td>14.5±8.4*</td>
<td>28.7±17.4*</td>
<td>87±5*</td>
</tr>
<tr>
<td>P. aeruginosa + Ab</td>
<td>3</td>
<td>13.4±12.5*</td>
<td>18.4±14.0*</td>
<td>79±20*</td>
</tr>
</tbody>
</table>

Data as mean±SD. *P < 0.05 compared with control group.

Results

Evidence for experimental pneumonia

Effect of P. aeruginosa on mortality of rats over 24 h. The mortality of rats with pneumonia was 50%. There was no difference in mortality between rats instilled with P. aeruginosa and rats instilled with both P. aeruginosa and anti–TNFα-antibody. All rats surviving to 24 h were apathetic and tachypneic, and gross examination confirmed a heterogenous but diffuse (~80%), bilateral pneumonia, with lung edema and pathologic lesions in all of the infected rats that were studied.

Bacteriology. Quantitative cultures of the instillate verified that 2–4×10^6 cfu P. aeruginosa/kg were instilled. In surviving rats, 10^6–10^7 cfu P. aeruginosa were recovered per gram of lung homogenate after 24 h (Table I). Blood samples were always culture negative, but 50% of the pleural lavage liquid cultures were positive. There were no significant differences in lung bacterial counts between the rats treated with anti–TNFα antibody vs. those not treated (Table I).

Bacteriological cultures were done at the time of spontaneous death in four rats that had been instilled with P. aeruginosa (n = 2) or P. aeruginosa and anti–TNFα antibody (n = 2). In these rats, all blood cultures were positive and lung homogenate quantitative cultures were greater than 10^6 cfu/g (Table I). Statistical tests were not done on the quantitative cultures because the number of animals was too small, but it was clear that in nonsurviving animals, the number of bacteria was greater than in the surviving rats.

Cell count in BAL. 24 h after instillation of P. aeruginosa, the total number of polymorphonuclear neutrophils and mononuclear cells recovered by BAL was greater (P < 0.05) than in the control rats (Table II). The predominant population of cells were neutrophils. The anti–TNFα antibodies in the airspaces did not modify the BAL cell count compared with control rats. Also, inhibition of the early TNFα peak by administering intraalveolar anti–TNFα antibody in P. aeruginosa–instilled rats did not reduce the inflammatory cell influx (Table II).

Histological examination. In animals inoculated with P. aeruginosa (n = 5) and killed at 24 h, many alveoli were filled with protein, fibrin, neutrophils, and variable quantities of erythrocytes and macrophages (Fig. 1 a). Ultrastructural examination of the lungs 24 h after P. aeruginosa instillation demonstrated that the alveolar epithelium had been denuded and the Fisher’s exact test were used to compare the different groups. We regarded P < 0.05 as statistically significant (26, 27).
in a few areas, providing morphologic evidence of alveolar epithelial barrier injury (Fig. 1 b).

**Bidirectional protein flux**

The histological data demonstrated evidence of increased permeability to the endothelial and epithelial barriers with edema fluid in the interstitium and in the airspaces 24 h after bacterial challenge (Fig. 1). When net protein flux was measured over 1 h in the rats with pneumonia 24 h after the instillation of bacteria, the accumulation of the plasma protein tracer $^{131}$I-albumin in the extravascular and in the airspaces of the lung was higher than in the control group, but did not quite reach statistical significance (Table III). Similarly, the mean flux of the alveolar protein tracer ($^{125}$I-albumin) over 1 h across the alveolar barrier was greater in the *P. aeruginosa* studies (Table III), although the difference did not reach statistical significance, probably because of the short time interval (1 h) of experiment.

**Alveolar liquid clearance in pneumonia**

The initial alveolar protein concentration was not different from the protein concentration of the instilled 5% albumin solution (initial alveolar/instillate protein concentration ratio $= 1.03 \pm 0.02$, as mean±SD, $n = 10$). In contrast, the concentration of the $^{125}$I-albumin was significantly decreased in the initial alveolar sample compared with that of the instilled albumin solution (initial alveolar [after 1 min]/instillate $^{125}$I ratio = $0.67 \pm 0.10$, as mean±SD, $n = 10$). Thus, this initial dilution of the labeled alveolar albumin tracer was secondary to the dilution by alveolar edema already present in the alveoli (as noted in Fig. 1 a). Because of the evidence for dilution of alveolar tracer to 67%, we assumed that the initial $^{125}$I-albumin concentration in the alveoli was 67% of the instilled albumin concentration.

---

**Table III. Effects of *P. aeruginosa*, Anti–TNFα Antibody and TNFα Treatments on Bidirectional Protein Permeability across the Lung Epithelial Barrier**

<table>
<thead>
<tr>
<th>Groups</th>
<th>No.</th>
<th>Alveolar protein tracer</th>
<th>Vascular protein tracer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Recovery of $^{125}$I-albumin in the lung</td>
<td>$^{131}$I-albumin extravascular plasma equivalents in the lung</td>
</tr>
<tr>
<td></td>
<td></td>
<td>% of instilled</td>
<td>ml</td>
</tr>
<tr>
<td>Control</td>
<td>6</td>
<td>97±1</td>
<td>0.10±0.04</td>
</tr>
<tr>
<td>Control + Ab</td>
<td>4</td>
<td>96±1</td>
<td>0.08±0.02</td>
</tr>
<tr>
<td><em>P. aeruginosa</em></td>
<td>10</td>
<td>94±5</td>
<td>0.12±0.04</td>
</tr>
<tr>
<td><em>P. aeruginosa</em> + Ab</td>
<td>6</td>
<td>92±3</td>
<td>0.15±0.08</td>
</tr>
<tr>
<td>TNFα</td>
<td>4</td>
<td>98±1</td>
<td>0.08±0.04</td>
</tr>
<tr>
<td>TNFα + prop</td>
<td>4</td>
<td>97±2</td>
<td>0.09±0.05</td>
</tr>
</tbody>
</table>

Data as mean±SD. Extravascular plasma equivalents in the lung = $^{131}$I-albumin in lung – ($^{131}$I-albumin in final blood sample × $Q_B$) / $^{131}$I-albumin in plasma averaged over the 1-h experiment. $Q_B$, blood volume in the lung (see Measurements in Methods). Extravascular plasma equivalents in the alveoli = $^{131}$I-albumin in final alveolar fluid/$^{131}$I-albumin in plasma averaged over the 1-h experiment.
tration was also 67% of the instilled concentration and used $^{125}$I-albumin concentration to estimate alveolar liquid clearance in these studies to provide another method for calculating alveolar liquid clearance besides the concentration of the instilled unlabeled protein.

Alveolar liquid clearance as measured by the increase in concentration of unlabeled protein, which was significantly increased in $P. aeruginosa$–instilled rats by 48% compared with controls (Fig. 2). Alveolar liquid clearance as measured by the increase of labeled alveolar protein tracer concentration was similarly increased by 50% in $P. aeruginosa$–instilled rats (Fig. 2).

Experiments without blood flow. In exsanguinated rats, the experiments corroborated data provided by the in vivo studies. With both labeled and unlabeled alveolar protein, a similar increase in alveolar liquid clearance occurred in the rats with pneumonia (Fig. 3).

Effect of amiloride and propranolol on alveolar liquid clearance in pneumonia

In both experiments with and without blood flow in pneumonia rats, amiloride resulted in a return of alveolar liquid clearance to basal levels; amiloride prevented the major part of the increase in alveolar liquid clearance (Figs. 2 and 3). In contrast, propranolol had no effect on the stimulated clearance (Figs. 2 and 3).

Also, measurements of alveolar liquid clearance using the increase of $^{125}$I-albumin concentration, based on the assump-
tion that the initial $^{125}$I-albumin concentration was 67% of the instilled concentration, were consistent with alveolar liquid clearance calculated from the increase of nonlabeled protein concentration (Figs. 2 and 3).

**Effect of anti–TNFα antibody on alveolar fluid clearance**

*TNFα* levels in lung homogenate tissue. High levels of lung homogenate *TNFα* were measured with a peak at 4 h in rats with pneumonia (Fig. 4). Because of this early peak of *TNFα*, neutralizing anti–TNFα antibody was instilled just before *P. aeruginosa* inoculum. With this protocol, rats that were instilled with both *P. aeruginosa* and neutralizing anti–TNFα antibody had a dose-dependent decrease in *TNFα* levels (Fig. 5).

Anti–TNFα antibody instilled alone 24 h before the experiment did not modify alveolar liquid clearance in Ab group (Fig. 6). However, in rats with pneumonia, the stimulated fraction of the alveolar liquid clearance, estimated with labeled or nonlabeled protein, was almost completely inhibited when an anti–TNFα antibody treatment was given (Fig. 6).

**Effect of *TNFα* instillation into the airspaces on alveolar fluid clearance**

*TNFα* (5 µg) was instilled with the albumin test solution at the beginning of the experiment in normal rats. *TNFα* significantly

---

**Figure 6.** Data (mean±SD) on alveolar liquid clearance in control, *P. aeruginosa*, anti–TNFα antibody alone, and *P. aeruginosa* + anti–TNFα antibody instilled. Alveolar liquid clearance was measured by the increase of the alveolar nonlabeled, (□), and labeled, (■), protein concentration. The anti–TNFα antibody prevented the *P. aeruginosa*–stimulated increase in alveolar liquid clearance. *P < 0.05 compared with control group.

---

**Figure 7.** Data (mean±SD) on alveolar liquid clearance in control, *TNFα* alone, and *TNFα* + propranolol–instilled rats. Alveolar liquid clearance was measured by the increase of the alveolar nonlabeled, (□), and labeled, (■), protein concentration. Administration of *TNFα* (5 µg) stimulated alveolar liquid clearance by 43%. This effect was not inhibited by propranolol (prop). *P < 0.05 compared with control group.

---

**Figure 8.** Effect of *P. aeruginosa* and *P. aeruginosa* + anti–TNFα antibody on the water to dry weight ratio after 24 h. Data as mean±SD. *P < 0.05 compared with control group. **P < 0.05 compared with *P. aeruginosa*. The anti–TNFα antibody treatment in pneumonia rats is associated with an increased water to dry weight ratio.
increased alveolar liquid clearance by 43%, as measured with labeled or non labeled protein (Fig. 7). As in rats with pneumonia experiments (Figs. 2 and 3), propranolol did not reduce the stimulatory effect of acute TNFα treatment on alveolar liquid clearance (Fig. 7).

Extravascular lung water
Extravascular lung water was increased by 12% \((P < 0.05)\) in rats with pneumonia compared with controls (Fig. 8). Also, rats with pneumonia treated with the anti–TNFα antibody had an even higher extravascular lung water than the untreated pneumonia rats (Fig. 8).

Airway pressure, body temperature, mean arterial pressure and oxygenation
Peak airway pressure and rectal temperature 24 h immediately after *P. aeruginosa* instillation were similar in all groups. No difference was found in systemic arterial pressure between the groups (Table IV). Oxygenation was significantly lower in the rats with pneumonia, with a major decrease in the PaO₂ (Table IV). In the anti–TNFα antibody–treated pneumonia rats, the mean PaO₂/FiO₂ ratio was 25% lower than in the untreated rats with pneumonia (Table IV), although this difference did not quite reach statistical significance.

### Discussion

Since alveolar epithelial barrier fluid transport is critical for the resolution of edema in patients with acute lung injury (1), we studied alveolar fluid clearance in a rat model of severe acute lung injury from pneumonia. Until recently, there had been few data available regarding the regulation of alveolar barrier function under experimental conditions that simulate acute lung injury in patients with adult respiratory distress syndrome (ARDS). One recent report indicated upregulation of alveolar epithelial sodium and fluid transport after hyperoxic exposure in rats (28), and we have reported catecholamine upregulation in septic shock (20). This experimental study was focused on the function of the alveolar epithelium after the development of gram-negative pneumonia in rats, 24 h after the instillation of *P. aeruginosa*. In spite of histologic evidence of some injury to the epithelial barrier, net alveolar liquid clearance was stimulated, a finding that is consistent with studies demonstrating the ability of the alveolar epithelial barrier to remove fluid in the presence of injury (1, 29). Therefore, we investigated the mechanisms that accounted for the increased alveolar liquid clearance in this in vivo model of gram-negative pneumonia.

Exposure to *P. aeruginosa* for 24 h induces pneumonia, based on bacteriologic criteria (Table I), physiologic criteria (hypoxemia) (Table IV), histologic evidence (Fig. 1), and a 50% spontaneous mortality rate. The presence of acute pneumonia was also demonstrated by a significant increase in the water to dry ratio of infected rats compared with those of control rats (Fig. 8). The lung injury in this acute bacterial model is characterized by an early influx of neutrophils and monocytes into the bronchoalveolar lavage fluid (Table II). All infected rats studied had a diffuse pneumonia as supported by gross examination of the lungs, associated with severe hypoxemia: 60% of the infected rats had a PaO₂/FiO₂ ratio < 200 mmHg, which is one criteria of ARDS (30).

To study the capacity of the alveolar epithelial barrier to remove fluid, we instilled a protein solution into the distal airspaces of the lung 24 h after the instillation of *P. aeruginosa*. There was a net increase in alveolar fluid clearance of 48% in the rats with pneumonia compared with control rats (Fig. 2). How can we be sure that this calculation of alveolar fluid clearance is accurate?

The purpose of these studies is to examine net alveolar epithelial fluid clearance. This model of pneumonia faithfully reproduces the clinical problem, which is diffuse but does not necessarily involve all alveoli. A recent study demonstrated that local *P. aeruginosa* instillation (approximately similar to the high dose used in our studies) induces contralateral lung injury (31).

Since there was histologic and gravimetric evidence of injury to the endothelial and epithelial barrier of the lung, several experimental approaches were used to evaluate carefully our method of alveolar fluid clearance measurement.

Calculation of alveolar liquid clearance required measurement of total protein concentration in the albumin test solution and in the alveolar fluid sampled by a catheter 1 h after instillation of the isosmolar albumin test solution. The concentrations of the native protein in the liquid sampled by a catheter wedged into the distal airways and obtained by alveolar micropuncture are the same (23). Also, the instilled 5% albumin solution with 125I-albumin was sampled over 1 min after instillation into the airspaces of 10 rats with pneumonia; no change in the total protein concentration was found because protein-rich edema fluid was already present in the alveoli. Therefore, we could use the total protein concentration measured in the albumin test solution as the initial alveolar protein concentration, and the total protein concentration measured in the fluid sampled from the airspaces as the final alveolar protein concentration in the equation for ALC calculation. Also, short time experiments were conducted (1 h) so the bidirectional protein movements were minimized in injured lungs, and two methods were used to measure the bidirectional protein flux across the alveolar epithelial barrier. The first method required measurement of the residual 125I-albumin (the alveolar protein tracer) in the lung as well as the accumulation of the 125I-albumin in the plasma. The latter method required measurement of 131I-albumin (the vascular protein tracer) in the air space compartment of the lung. Thus, by using both a vascular and an alveolar protein tracer, the magnitude of the bidirectional protein flux after lung injury can be evaluated. In these conditions, because there was not a marked change in epithe-

### Table IV. Effect of *P. aeruginosa* and Anti-TNFα Antibody Instillation on Baseline PaO₂/FiO₂ and Mean Systemic Arterial Pressure after 24 h

<table>
<thead>
<tr>
<th>Groups</th>
<th>No.</th>
<th>PaO₂/FiO₂</th>
<th>Mean systemic arterial pressure mmHg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>6</td>
<td>490±45</td>
<td>131±10</td>
</tr>
<tr>
<td>Control + Ab</td>
<td>5</td>
<td>448±40</td>
<td>125±7</td>
</tr>
<tr>
<td><em>P. aeruginosa</em></td>
<td>10</td>
<td>170±132*</td>
<td>110±34</td>
</tr>
<tr>
<td><em>P. aeruginosa</em> + Ab</td>
<td>6</td>
<td>127±101*</td>
<td>102±38</td>
</tr>
</tbody>
</table>

Data as mean±SD. *P < 0.05 compared with control groups. Difference between the two groups with pneumonia did not reach a statistical significance.
lial permeability after 1 h of experiment in rats instilled with *P. aeruginosa*, the alveolar volume can be estimated by comparing the final with the initial protein concentration to calculate the alveolar liquid clearance, confirming the validity of the measurement of alveolar liquid clearance using nonlabeled protein.

In the alveolar space, as expected, $^{125}$I-albumin concentration was significantly decreased in the alveolar sample obtained 1 min after instillation compared with that of the instilled albumin solution (initial alveolar/instillate $^{125}$I ratio = 0.67 ± 0.10), because the protein tracer was diluted by nonlabeled protein-rich alveolar edema fluid. Therefore, we also calculated alveolar liquid clearance using the increase in $^{125}$I-albumin concentration over 1 h, taking into account the dilution of the labeled alveolar albumin (estimated initial $^{125}$I-albumin = cpm, × 0.67). The alveolar liquid clearance calculations were almost identical using the labeled and unlabeled albumin concentration over 1 h (Figs. 2 and 3). Since we measured a net increase in fluid movement across the alveolar epithelial barrier, the epithelium must have been sufficiently intact to remove excess alveolar fluid.

To use a third method to confirm our calculations, we eliminated bidirectional protein movement by exsanguinating rats and measuring alveolar fluid clearance over 1 h as we have done in sheep (17) and in excised human lungs (2). A comparable increase in alveolar liquid clearance was found in these experiments with and without blood flow (Figs. 2 and 3). This finding further validated the results of previous in vivo studies that had demonstrated that the process of alveolar fluid reabsorption does not depend on the blood flow in short term studies (2, 32).

The addition of amiloride to the instilled protein solution, in experiments both with (Fig. 2) and without (Fig. 3) blood flow, resulted in a return of alveolar liquid clearance to basal levels. In our previous studies, we reported that amiloride inhibited 44% of alveolar liquid clearance in control rats (7, 11). The dose of 2 × $10^{-3}$ M amiloride was used because 50% of amiloride is bound to protein (33) and a significant fraction escaped from the airspaces (34). The increased clearance in rats with pneumonia depended on a stimulatory uptake of sodium across the alveolar epithelium. This effect could be attributed either to a recruitment of new channels, or to an increase in the open-time probability of existing channels (6). The possibility that other amiloride-sensitive Na⁺ channels, such as Na⁺–H⁺ antipporter or Na⁺–Ca²⁺, contribute to the stimulatory effect in vivo cannot be excluded (35).

After we determined that the stimulated liquid clearance from the distal airspaces in infected rats was dependent on an increase in sodium-dependent uptake by lung epithelial cells, we explored the potential influence of adrenergic mechanisms on clearance (20). Several studies have reported dense beta-receptor binding in the alveolar walls in different species, including rats and humans (36–39). Also, exogenous administration of beta-adrenergic agonists stimulates active sodium transport across the epithelial barrier of the lung in vivo models (3, 11), in perfused rat lungs (40, 41), and in vitro models (42, 43). Additionally, septic shock in rats accelerates alveolar epithelial liquid clearance by release of endogenous epinephrine (20). In this study, the increase in alveolar liquid clearance in rats with pneumonia both with (Fig. 2) and without (Fig. 3) blood flow was comparable with the increase reported in beta-adrenergic therapy (3, 11). However, propranolol, a beta-adrenergic antagonist, did not reduce this effect. Therefore, the upregulation of net alveolar fluid clearance was not mediated by stimulation of epithelial beta-receptors in this 24-h model of bacterial pneumonia. One explanation could be that the release of endogenous catecholamines occurs early and return to normal levels in pneumonia. It has been shown that rats treated with intravenous catecholamines occur occurs early and return to normal levels in pneumonia. It has been shown that rats treated with intravenous endotoxin have an immediate rise in plasma epinephrine, but a decrease over time so that plasma epinephrine concentrations after 6 h are < 20% of the initial value (44). Thus, while endogenous release of catecholamines may either protect against alveolar edema or hasten its resolution in some pathological conditions, this mechanism did not account for the stimulated clearance in these 24-h studies of rats with pneumonia.

The probable role of TNFα in endotoxic challenge in human subjects (45) and in patients with septic-induced ARDS (46, 47) has been well studied. Some experimental studies implicate TNFα in the increase of lung endothelial or epithelial permeability (13, 48). However, it is also known that TNFα can increase sodium-dependent amino acid transport in rat hepatocytes (14). Therefore, our third objective was to test the hypothesis that TNFα could mediate the increase in alveolar fluid clearance in this 24-h model of severe bacterial pneumonia. We eliminated 70% of the rise in TNFα detected in the lung by instilling the anti–TNFα antibody before *P. aeruginosa*. In rats with pneumonia that were pretreated with anti–TNFα antibody, alveolar liquid clearance was comparable to those measured in control rats (Fig. 6). In addition, instillation of TNFα in normal rats increased alveolar liquid clearance by 43% compared with controls (Fig. 7). These results indicate that the in vivo administration of live *P. aeruginosa* into the distal airspaces results in an increase of the alveolar epithelial sodium uptake, which can be upregulated by a TNFα-dependent mechanism. The stimulated alveolar liquid clearance with acute TNFα treatment and *P. aeruginosa* pneumonia were not reduced by propranolol (Fig. 7), indicating that this effect is not mediated by an adrenergic mechanism.

The results are internally consistent. For example, separate indices suggested that anti–TNFα antibody pretreatment of infected rats resulted in a worsening of lung injury. Pretreated rats with pneumonia had more pulmonary edema (Fig. 8) and a tendency toward worse oxygenation (Table IV) compared with infected rats without pretreatment. Interestingly, the BAL cell counts of the two groups were the same (Table II).

Cytokines are endogenous proteins that play a crucial role in host defenses against infection. Yet, when proinflammatory cytokines are produced in excess, they can trigger a cascade of deleterious events resulting in shock and multiple organ failure. While TNFα has been one of the proximal cytokines implicated in the pathophysiology of septic shock, very different effects were observed with anti–TNFα antibody in experimental infectious models. In mice, anti–TNFα antibody had a protective effect against endotoxin (50). On the contrary, in rats with streptococcal B sepsis, the mortality was the same between untreated and treated anti-TNFα antibody groups (15).

What is the possible cellular basis for the TNFα effect in
these studies? There are two distinct TNF receptors that are expressed in a wide variety of tissues, including A549 cells (a cell line with features of alveolar type II cells) (51, 52). After binding to the receptor, TNFs may induce a variety of intracellular signals. Since TNFs is known to decrease cAMP (53, 54), it is not likely that the enhanced sodium and fluid absorption in these studies is mediated by cAMP, a second messenger that is known to increase vectorial sodium transport in alveolar type II cells (35, 40). However, interestingly, TNFs does regulate G proteins (55), and recently G proteins have been reported to regulate amiloride-sensitive sodium uptake in fetal alveolar type II epithelial cells (56). There is also recent evidence that TNF-α can increase uptake of sodium into cells by inserting an ion channel into cell membranes (57).

In summary, acute P. aeruginosa pneumonia in rats results in a marked upregulation of the rate of net alveolar epithelial sodium and fluid clearance. The upregulation of alveolar fluid clearance depends in part on a TNF stimulation of alveolar epithelial sodium uptake, a novel mechanism that may have important clinical implications.

Acknowledgments

The authors thank Dr. Kouyoumdjian, Brigitte Boissier, and Liliane Leclerc for their technical assistance in carrying out these studies and Anton Ford for reviewing the manuscript.

This study was supported by Association pour la Recherche sur le Cancer grant ARC-6908 and by a National Institutes of Health grant HL-51854 to M.A. Matthay.

References


